The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects

Diabetes and Vascular Disease Research

Volumn 11, Issue 6, 2014, Pages 440-447

  Hanf, Rémy ^a   Millatt, Lesley J ^a   Cariou, Bertrand ^b   Noel, Benoit ^a   Rigou, Géraldine ^a   Delataille, Philippe ^a   Daix, Valérie ^a   Hum, Dean W ^a   Staels, Bart ^c,d,e,f  

^a Genfit SA   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d UMR 1011 ^*  (France)

^e UNIV LILLE   (France)

^f EGID FR3508 European Genomics Institute of Diabetes   (France)

Author keywords

anti diabetic; dual PPAR agonist; GFT505; lipid metabolism; PPAR; safety

Indexed keywords

ADIPONECTIN; ALEGLITAZAR; GFT 505; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPENYL)PHENOXYL)-2-METHYLPROPANOIC ACID; CHALCONE DERIVATIVE; GLUCOSE BLOOD LEVEL; LIPID; PROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; BLOOD LEVEL; BONE MARROW CELL; CARDIOTOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART WEIGHT; HISTOLOGY; INSULIN SENSITIVITY; LEUKOCYTE DIFFERENTIAL COUNT; MACACA FASCICULARIS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; AGONISTS; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; DRUG SCREENING; RANDOMIZATION;

ANIMALS; BLOOD GLUCOSE; CHALCONES; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; LIPIDS; MALE; MICE; PPAR ALPHA; PPAR DELTA; PROPIONATES; RANDOM ALLOCATION;

EID: 84907060427     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114548027     Document Type: Review

References (16)

1. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996 ; 1302: 93-109
2. Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011 ; 217: 492-498
3. Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol. 2012 ; 5: 272-281
4. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA. 2006 ; 103: 3444-3449
5. Winzell MS, Wulff EM, Olsen GS, et al. Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice. Eur J Pharmacol. 2010 ; 626: 297-305
6. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008 ; 57: 332-339
7. Feldman PL, Lambert MH, Henke BR. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?. Curr Top Med Chem. 2008 ; 8: 728-749
8. Lecka-Czernik B. Aleglitazar, a dual PPARalpha and PPARgamma agonist for the potential oral treatment of type 2 diabetes mellitus. IDrugs. 2010 ; 13: 793-801
9. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005 ; 294: 2581-2586
10. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab. 2012 ; 23: 205-215
11. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 ; 311: 1515-1525
12. Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care. 2011 ; 34: 2008-2014
13. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013 ; 36: 2923-2930
14. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002 ; 92: 536-541
15. Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005 ; 146: 1226-1235
16. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013 ; 58: 1941-1952